Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer
NCT ID: NCT01514669
Last Updated: 2025-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
75 participants
OBSERVATIONAL
2012-01-01
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analyzing the Composition of Tears to Identify Cancer
NCT00574678
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients
NCT02853097
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
NCT00908739
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
NCT05223218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No treatment
No Tx, this is observational
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who present for the evaluation of an abnormal exam or test (elevated PSA, abnormal DRE, etc.)
3. Patients who present for the evaluation of a palpable nodule or induration on prostate exam
4. Patients who meet the requirements of Group 1, 2, or 3 of the protocol
Exclusion Criteria
2. Concurrent eye infection or trauma, including active conjunctivitis
3. Abnormal production of tears (too much or too little)
4. Any other conditions the PI or staff feels will not fulfill the criteria for study entry or will place the subject in a harmful environment
5. Atypia on prostate biopsy report
35 Years
85 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Arkansas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan Diekman, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Arkansas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
133719
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.